Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Feeding-suppressive properties of new orally active NPY Y5 antagonist

April 24, 2006

Bio-E-Gel NDA accepted for review

April 24, 2006

Phase II studies show anemia correction with CERA in chronic kidney disease

April 24, 2006

Novel cathepsin K inhibitor as a potential antiresorptive agent to treat osteoporosis

April 21, 2006

Japanese approval for Nu-Lotan in diabetic nephropathy

April 21, 2006

Zometa receives new approval in Japan

April 21, 2006

Japanese approval for Cetrotide for premature ovulation

April 21, 2006

Technosphere Insulin System improves HbA1c in phase II study

April 21, 2006

Schering-Plough selects compound for metabolic disease from collaboration

April 21, 2006

Roche submits BLA for CERA

April 20, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
NTX-819, a novel mGlu7 NAM for psychiatric disorders
BioWorld Science
Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on...